Skip to main content
OpenTrials
Completed

NCT Number: NCT03482557

Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening

This research study is evaluating whether contrast enhanced mammography can be used as an alternative to breast Magnetic Resonance Imaging (MRI) for cancer screening

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–110 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Beth Israel Deaconess

Boston, Massachusetts, 02215, United States

About this study

Mammography is the main way to help find breast cancers early so they can be treated. Unfortunately, mammography does not work as well in women who have dense breast tissue or who are at high-risk for breast cancer. In these women, breast MRI is also used to help find breast cancers.

Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone. This is similar to breast MRI.

For this study, participants who had both CEM and MRI evaluating a finding that initiated from a screening exam will be included. Radiologists will compare the images to see if the contrast enhanced mammograms and the breast MRI find the same number of breast cancers. If the investigators find they perform similarly, then contrast mammography may be used to aid in breast cancer screening in the future.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • CESM and MRI exam performed within 3 months of one another.
  • CESM and breast MRI exams must be performed as part of imaging work-up based on a screening exam of any type (mammography, tomosynthesis, ultrasound, and MRI)
  • CESM studies will include at least four low energy and four recombined images (LCC, LMLO, RCC, RMLO).
  • MRI exams will include at least fluid sensitive sequence, multi-phase T1-weighted

Exclusion criteria

  • Imaging sets with implants.
  • Imaging sets in which a biopsy or surgical intervention was performed since the most recent screening exam, prior to acquisition of the study MRI or CESM.
  • Imaging sets in which a biopsy was recommended, but biopsy was not performed and 2 year imaging follow-up is not available

Treatment and study plan

CESM

Device

Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone

Other names: Contrast Enhanced Spectral Mammography

MRI

Device

MRI uses magnets to create a detailed image of the tissues and bones inside of the body

Other names: Magnetic Resonance Imaging

Primary outcomes

  1. Area Under the Curve for Cancer Detection Rates of CESM Compared With Breast MRI for Breast Cancer Screening

    Time frame: 2 years

    We will determine whether CESM is non-inferior to breast MRI for breast cancer detection by comparing cancer detection rates on both studies using a multi-case multi-reader study model.

Secondary outcomes

  1. Area Under the Curve for Cancer Detection Rates of CESM Compared With Abbreviated Breast MRI for Breast Cancer Screening

    Time frame: 2 years

    Radiologist readers evaluated CEM and abbreviated MRI in 132 patients, some who had cancer and some who did not. The area under the curve was determine for each reader for each exam type.

  2. Area Under the Curve for Cancer Detection Rates of CESM Compared With Conventional 2d Mammography for Breast Cancer Screening

    Time frame: 2 years

    We will determine whether CESM is superior to conventional 2D mammographic screening using a multi-case multi-reader study model.

Sponsors and collaborators

Lead sponsor

Beth Israel Deaconess Medical Center

Other

Collaborators

  • Dana-Farber Cancer Institute
  • GE Healthcare

Registry information

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Mar 29, 2018
Registry last updated
Jan 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.